NovoCure Limited [NASDAQ: NVCR] loss -4.21% or -2.86 points to close at $65.03 with a heavy trading volume of 1238502 shares. It opened the trading session at $65.71, the shares rose to $67.3781 and dropped to $63.63, the range by which the price of stock traded the whole day. The daily chart for NVCR points out that the company has recorded -17.97% loss over the past six months. However, it is still -21.78% lower than its most recent low trading price.
If we look at the average trading volume of 939.89K shares, NVCR reached to a volume of 1238502 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Here is what top equities market gurus are saying about NovoCure Limited [NVCR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVCR shares is $79.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVCR stock is a recommendation set at 2.60. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for NovoCure Limited shares, keeping their opinion on the stock as Perform, with their previous recommendation back on June 01, 2020. The new note on the price target was released on May 01, 2020, representing the official price target for NovoCure Limited stock. Previously, the target price had yet another raise to $58, while Evercore ISI analysts kept a Underperform rating on NVCR stock. On March 05, 2020, analysts increased their price target for NVCR shares from 85 to 90.
The Average True Range (ATR) for NovoCure Limited is set at 3.24, with the Price to Sales ratio for NVCR stock in the period of the last 12 months amounting to 15.63. The Price to Book ratio for the last quarter was 26.87, with the Price to Cash per share for the same quarter was set at 3.63. Price to Free Cash Flow for NVCR in the course of the last twelve months was 293.89 with Quick ratio for the last quarter at 5.20.
Trading performance analysis for NVCR stock
NovoCure Limited [NVCR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.99. With this latest performance, NVCR shares gained by 3.41% in over the last four-week period, additionally sinking by -17.97% over the last 6 months – not to mention a rise of 16.58% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVCR stock in for the last two-week period is set at 47.56, with the RSI for the last a single of trading hit 46.22, and the three-weeks RSI is set at 47.88 for NovoCure Limited [NVCR]. The present Moving Average for the last 50 days of trading for this stock 66.84, while it was recorded at 67.90 for the last single week of trading, and 76.84 for the last 200 days.
NovoCure Limited [NVCR]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and NovoCure Limited [NVCR] shares currently have an operating margin of -0.17 and a Gross Margin at +74.87. NovoCure Limited’s Net Margin is presently recorded at -2.06.
Return on Total Capital for NVCR is now -0.18, given the latest momentum, and Return on Invested Capital for the company is -2.25. Return on Equity for this stock declined to -4.38, with Return on Assets sitting at -1.77. When it comes to the capital structure of this company, NovoCure Limited [NVCR] has a Total Debt to Total Equity ratio set at 77.23. Additionally, NVCR Total Debt to Total Capital is recorded at 43.58, with Total Debt to Total Assets ending up at 35.08. Long-Term Debt to Equity for the company is recorded at 75.10, with the Long-Term Debt to Total Capital now at 42.38.
Reflecting on the efficiency of the workforce at the company, NovoCure Limited [NVCR] managed to generate an average of -$9,246 per employee. Receivables Turnover for the company is 6.32 with a Total Asset Turnover recorded at a value of 0.86.NovoCure Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.20 and a Current Ratio set at 5.50.
NovoCure Limited [NVCR]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, NovoCure Limited posted -0.01/share EPS, while the average EPS was predicted by analysts to be reported at -0.07/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 85.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVCR.
An analysis of insider ownership at NovoCure Limited [NVCR]
There are presently around $4,784 million, or 71.50% of NVCR stock, in the hands of institutional investors. The top three institutional holders of NVCR stocks are: FMR LLC with ownership of 11,839,159, which is approximately -2.794% of the company’s market cap and around 10.30% of the total institutional ownership; BAILLIE GIFFORD & CO, holding 7,736,618 shares of the stock with an approximate value of $525.24 million in NVCR stocks shares; and VANGUARD GROUP INC, currently with $503.63 million in NVCR stock with ownership of nearly 2.273% of the company’s market capitalization.
152 institutional holders increased their position in NovoCure Limited [NASDAQ:NVCR] by around 4,918,197 shares. Additionally, 127 investors decreased positions by around 4,050,917 shares, while 33 investors held positions by with 61,498,606 shares. The mentioned changes placed institutional holdings at 70,467,720 shares, according to the latest SEC report filing. NVCR stock had 48 new institutional investments in for a total of 1,251,668 shares, while 41 institutional investors sold positions of 423,251 shares during the same period.